Aldeyra Therapeutics Inc. - ALDX Net earnings per one share for the last twelve months

Aldeyra Therapeutics (ALDX) develops treatments for allergies and dry eye, ensuring stable demand through the regular use of its solutions. Growth is driven by the FDA approval of reproxalap and the expansion of its metabolic drug portfolio. The company is currently actively preparing for the mass production of innovative products. The price action shown below confirms these data, and the EPS TTM stands at 56.00.
Aldeyra Therapeutics Inc. - analytical breakdowns and key metrics (ALDX)

This indicator measures the rolling annual growth rate of earnings per share, neutralizing quarterly reporting gaps. Analyzing the 12-month YoY change in net income per share reveals the actual business dynamics, eliminating market illusions. For the investor, this serves as a tool for assessing capitalization efficiency. In Aldeyra Therapeutics (ALDX), such a metric reflects the financial results of elite ophthalmologists motivated by bonuses for successful clinical trials.